User login
Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.
Largest-Ever Study of Pemphigus and Pemphigoid Launched
A natural history registry that will provide a complete picture of each patient’s experience with pemphigus and pemphigoid has been launched by the International Pemphigus and Pemphigoid Foundation with NORD. This study will be open to patient worldwide to advance understanding and treatments for these rare conditions. The registry will be maintained on a platform developed by NORD in line with its mission to seek treatments or cures for all rare diseases. The project is supported by a cooperative agreement between NORD and the US Food and Drug Administration (FDA).
A natural history registry that will provide a complete picture of each patient’s experience with pemphigus and pemphigoid has been launched by the International Pemphigus and Pemphigoid Foundation with NORD. This study will be open to patient worldwide to advance understanding and treatments for these rare conditions. The registry will be maintained on a platform developed by NORD in line with its mission to seek treatments or cures for all rare diseases. The project is supported by a cooperative agreement between NORD and the US Food and Drug Administration (FDA).
A natural history registry that will provide a complete picture of each patient’s experience with pemphigus and pemphigoid has been launched by the International Pemphigus and Pemphigoid Foundation with NORD. This study will be open to patient worldwide to advance understanding and treatments for these rare conditions. The registry will be maintained on a platform developed by NORD in line with its mission to seek treatments or cures for all rare diseases. The project is supported by a cooperative agreement between NORD and the US Food and Drug Administration (FDA).
Applications Are Being Accepted for Free Family Rare Disease Summer Camp
NORD is once again partnering with The Hole in the Wall Gang Camp on a rare disease summer family camp in Connecticut. Families living in the Northeast may submit applications now for this free weekend of fun. The camp is located in Ashford, CT, and will take place June 1 to 4.
NORD is once again partnering with The Hole in the Wall Gang Camp on a rare disease summer family camp in Connecticut. Families living in the Northeast may submit applications now for this free weekend of fun. The camp is located in Ashford, CT, and will take place June 1 to 4.
NORD is once again partnering with The Hole in the Wall Gang Camp on a rare disease summer family camp in Connecticut. Families living in the Northeast may submit applications now for this free weekend of fun. The camp is located in Ashford, CT, and will take place June 1 to 4.
Film Festival Devoted to Rare Diseases Scheduled for October
A rare disease film festival will take place October 3 in Boston. Filmmakers whose work addresses issues of concern to rare disease patients may submit their work. By shining a light on the challenges that people with rare diseases and their loved ones face, the organizers hope to inspire people to take positive action to help others.
A rare disease film festival will take place October 3 in Boston. Filmmakers whose work addresses issues of concern to rare disease patients may submit their work. By shining a light on the challenges that people with rare diseases and their loved ones face, the organizers hope to inspire people to take positive action to help others.
A rare disease film festival will take place October 3 in Boston. Filmmakers whose work addresses issues of concern to rare disease patients may submit their work. By shining a light on the challenges that people with rare diseases and their loved ones face, the organizers hope to inspire people to take positive action to help others.
Save the Date for the 2017 NORD Summit
NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit will take place October 16-17 in Washington DC. The event brings together more than 500 attendees, including medical professionals, patient advocates, NIH and FDA officials, and those developing diagnostics and treatments for patients with rare diseases. The Summit is open to all. Sign up to receive updates on the Summit and/or other upcoming events.
NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit will take place October 16-17 in Washington DC. The event brings together more than 500 attendees, including medical professionals, patient advocates, NIH and FDA officials, and those developing diagnostics and treatments for patients with rare diseases. The Summit is open to all. Sign up to receive updates on the Summit and/or other upcoming events.
NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit will take place October 16-17 in Washington DC. The event brings together more than 500 attendees, including medical professionals, patient advocates, NIH and FDA officials, and those developing diagnostics and treatments for patients with rare diseases. The Summit is open to all. Sign up to receive updates on the Summit and/or other upcoming events.
NORD Rare Action Network™ Releases State Policy Legislative Tracker
The NORD Rare Action Network™ has released its Spring 2017 State Policy Legislative Tracker showing–state-by-state–legislation that is being tracked to improve the lives of those affected by rare diseases. Currently, action is underway in 42 states and the District of Columbia.
The NORD Rare Action Network™ has released its Spring 2017 State Policy Legislative Tracker showing–state-by-state–legislation that is being tracked to improve the lives of those affected by rare diseases. Currently, action is underway in 42 states and the District of Columbia.
The NORD Rare Action Network™ has released its Spring 2017 State Policy Legislative Tracker showing–state-by-state–legislation that is being tracked to improve the lives of those affected by rare diseases. Currently, action is underway in 42 states and the District of Columbia.
NORD and Neurology Reviews Publish Special Report
NORD and Neurology Reviews together have published the third annual Rare Neurological Disease Special Report in print and digital editions to promote awareness and understanding of rare neurological diseases among medical professionals. The publication includes articles on the efficacy of cannabis in treating children with rare and refractory epilepsy, delays in diagnosis and treatment of infantile spasms, telemedicine, new and potential therapies for rare neuromuscular disorders, and the clinical therapeutic potential of gene therapy.
NORD and Neurology Reviews together have published the third annual Rare Neurological Disease Special Report in print and digital editions to promote awareness and understanding of rare neurological diseases among medical professionals. The publication includes articles on the efficacy of cannabis in treating children with rare and refractory epilepsy, delays in diagnosis and treatment of infantile spasms, telemedicine, new and potential therapies for rare neuromuscular disorders, and the clinical therapeutic potential of gene therapy.
NORD and Neurology Reviews together have published the third annual Rare Neurological Disease Special Report in print and digital editions to promote awareness and understanding of rare neurological diseases among medical professionals. The publication includes articles on the efficacy of cannabis in treating children with rare and refractory epilepsy, delays in diagnosis and treatment of infantile spasms, telemedicine, new and potential therapies for rare neuromuscular disorders, and the clinical therapeutic potential of gene therapy.
NORD Announces Recipients of 2017 Rare Impact Awards
Honorees at NORD’s 2017 Rare Impact Awards will include three clinicians and researchers with expertise in rare diseases. They are Robert Desnick, MD, PhD, of Mount Sinai Hospital and the Icahn School of Medicine in New York City; Frederick Kaplan, MD, of the Perelman School of Medicine at the University of Pennsylvania; and Cynthia Tifft, MD, PhD, of the National Institutes of Health. The three, along with other honorees, will be recognized for their work to improve the lives of patients affected by rare diseases.
The annual charity event will take place this year on May 18 at the Ronald Reagan Building and International Trade Center Amphitheatre in Washington DC. The event is open to the public and is a fundraiser to support NORD programs and services for all individuals who have rare diseases.
Honorees at NORD’s 2017 Rare Impact Awards will include three clinicians and researchers with expertise in rare diseases. They are Robert Desnick, MD, PhD, of Mount Sinai Hospital and the Icahn School of Medicine in New York City; Frederick Kaplan, MD, of the Perelman School of Medicine at the University of Pennsylvania; and Cynthia Tifft, MD, PhD, of the National Institutes of Health. The three, along with other honorees, will be recognized for their work to improve the lives of patients affected by rare diseases.
The annual charity event will take place this year on May 18 at the Ronald Reagan Building and International Trade Center Amphitheatre in Washington DC. The event is open to the public and is a fundraiser to support NORD programs and services for all individuals who have rare diseases.
Honorees at NORD’s 2017 Rare Impact Awards will include three clinicians and researchers with expertise in rare diseases. They are Robert Desnick, MD, PhD, of Mount Sinai Hospital and the Icahn School of Medicine in New York City; Frederick Kaplan, MD, of the Perelman School of Medicine at the University of Pennsylvania; and Cynthia Tifft, MD, PhD, of the National Institutes of Health. The three, along with other honorees, will be recognized for their work to improve the lives of patients affected by rare diseases.
The annual charity event will take place this year on May 18 at the Ronald Reagan Building and International Trade Center Amphitheatre in Washington DC. The event is open to the public and is a fundraiser to support NORD programs and services for all individuals who have rare diseases.
Flesh-Colored Nodule With Underlying Sclerotic Plaque
The Diagnosis: Collision Tumor
Excisional biopsy and histopathological examination demonstrated a collision tumor composed of a benign intradermal melanocytic nevus, tumor of follicular infundibulum, and an underlying sclerosing epithelial neoplasm, with a differential diagnosis of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma, and microcystic adnexal carcinoma (Figure).
Common acquired melanocytic nevus presents clinically as a macule, papule, or nodule with smooth regular borders. The pigmented variant displays an evenly distributed pigment on the lesion. Intradermal melanocytic nevus often presents as a flesh-colored nodule, as in our case. Histopathologically, benign intradermal nevus typically is composed of a proliferation of melanocytes that exhibit dispersion as they go deeper in the dermis and maturation that manifests as melanocytes becoming smaller and more spindled in the deeper portions of the lesion.1 These 2 characteristics plus the bland cytology seen in the present case confirm the benign characteristic of this lesion (Figure, B).
In addition to the benign intradermal melanocytic nevus, an adjacent tumor of follicular infundibulum was noted. Tumor of follicular infundibulum is a rare adnexal tumor. It occurs frequently on the head and neck and shows some female predominance.2,3 Multiple lesions and eruptive lesions are rare forms that also have been reported.4 Histopathologically, the tumor demonstrates an epithelial plate that is present in the papillary dermis and is connected to the epidermis at multiple points with attachment to the follicular outer root sheath. Peripheral palisading is characteristically present above an eosinophilic basement membrane (Figure, A). Rare reports have documented sebaceous and eccrine differentiation.5,6
Tumor of follicular infundibulum has been reported to be associated with other tumors. Organoid nevus (nevus sebaceous), trichilemmal tumor, and fibroma have been reported to occur as a collision tumor with tumor of follicular infundibulum. An association with Cowden disease also has been described.7 Biopsies that represent partial samples should be interpreted cautiously, as step sections can reveal basal cell carcinoma.
The term sclerosing epithelial neoplasm describes tumors that share a paisley tielike epithelial pattern and sclerotic stroma. Small specimens often require clinicopathologic correlation (Figure, C). The differential diagnosis includes morpheaform basal cell carcinoma, desmoplastic trichoepithelioma, and microcystic adnexal carcinoma. A panel of stains using Ber-EP4, PHLDA1, cytokeratin 15, and cytokeratin 19 has been proposed to help differentiate these entities.8 CD34 and cytokeratin 20 also have been used with varying success in small specimens.9,10
- Ferringer T, Peckham S, Ko CJ, et al. Melanocytic neoplasms. In: Elston DM, Ferringer T, eds. Dermatopathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2014:105-109.
- Headington JT. Tumors of the hair follicle. Am J Pathol. 1976;85:480-505.
- Davis DA, Cohen PR. Hair follicle nevus: case report and review of the literature. Pediatr Dermatol. 1996;13:135-138.
- Ikeda S, Kawada J, Yaguchi H, et al. A case of unilateral, systematized linear hair follicle nevi associated with epidermal nevus-like lesions. Dermatology. 2003;206:172-174.
- Mehregan AH. Hair follicle tumors of the skin. J Cutan Pathol. 1985;12:189-195.
- Mahalingam M, Bhawan J, Finn R, et al. Tumor of the follicular infundibulum with sebaceous differentiation. J Cutan Pathol. 2001;28:314-317.
- Cribier B, Grosshans E. Tumor of the follicular infundibulum: a clinicopathologic study. J Am Acad Dermatol. 1995;33:979-984.
- Sellheyer K, Nelson P, Kutzner H, et al. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40:363-370.
- Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311-315.
- Smith KJ, Williams J, Corbett D, et al. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25:464-471.
The Diagnosis: Collision Tumor
Excisional biopsy and histopathological examination demonstrated a collision tumor composed of a benign intradermal melanocytic nevus, tumor of follicular infundibulum, and an underlying sclerosing epithelial neoplasm, with a differential diagnosis of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma, and microcystic adnexal carcinoma (Figure).
Common acquired melanocytic nevus presents clinically as a macule, papule, or nodule with smooth regular borders. The pigmented variant displays an evenly distributed pigment on the lesion. Intradermal melanocytic nevus often presents as a flesh-colored nodule, as in our case. Histopathologically, benign intradermal nevus typically is composed of a proliferation of melanocytes that exhibit dispersion as they go deeper in the dermis and maturation that manifests as melanocytes becoming smaller and more spindled in the deeper portions of the lesion.1 These 2 characteristics plus the bland cytology seen in the present case confirm the benign characteristic of this lesion (Figure, B).
In addition to the benign intradermal melanocytic nevus, an adjacent tumor of follicular infundibulum was noted. Tumor of follicular infundibulum is a rare adnexal tumor. It occurs frequently on the head and neck and shows some female predominance.2,3 Multiple lesions and eruptive lesions are rare forms that also have been reported.4 Histopathologically, the tumor demonstrates an epithelial plate that is present in the papillary dermis and is connected to the epidermis at multiple points with attachment to the follicular outer root sheath. Peripheral palisading is characteristically present above an eosinophilic basement membrane (Figure, A). Rare reports have documented sebaceous and eccrine differentiation.5,6
Tumor of follicular infundibulum has been reported to be associated with other tumors. Organoid nevus (nevus sebaceous), trichilemmal tumor, and fibroma have been reported to occur as a collision tumor with tumor of follicular infundibulum. An association with Cowden disease also has been described.7 Biopsies that represent partial samples should be interpreted cautiously, as step sections can reveal basal cell carcinoma.
The term sclerosing epithelial neoplasm describes tumors that share a paisley tielike epithelial pattern and sclerotic stroma. Small specimens often require clinicopathologic correlation (Figure, C). The differential diagnosis includes morpheaform basal cell carcinoma, desmoplastic trichoepithelioma, and microcystic adnexal carcinoma. A panel of stains using Ber-EP4, PHLDA1, cytokeratin 15, and cytokeratin 19 has been proposed to help differentiate these entities.8 CD34 and cytokeratin 20 also have been used with varying success in small specimens.9,10
The Diagnosis: Collision Tumor
Excisional biopsy and histopathological examination demonstrated a collision tumor composed of a benign intradermal melanocytic nevus, tumor of follicular infundibulum, and an underlying sclerosing epithelial neoplasm, with a differential diagnosis of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma, and microcystic adnexal carcinoma (Figure).
Common acquired melanocytic nevus presents clinically as a macule, papule, or nodule with smooth regular borders. The pigmented variant displays an evenly distributed pigment on the lesion. Intradermal melanocytic nevus often presents as a flesh-colored nodule, as in our case. Histopathologically, benign intradermal nevus typically is composed of a proliferation of melanocytes that exhibit dispersion as they go deeper in the dermis and maturation that manifests as melanocytes becoming smaller and more spindled in the deeper portions of the lesion.1 These 2 characteristics plus the bland cytology seen in the present case confirm the benign characteristic of this lesion (Figure, B).
In addition to the benign intradermal melanocytic nevus, an adjacent tumor of follicular infundibulum was noted. Tumor of follicular infundibulum is a rare adnexal tumor. It occurs frequently on the head and neck and shows some female predominance.2,3 Multiple lesions and eruptive lesions are rare forms that also have been reported.4 Histopathologically, the tumor demonstrates an epithelial plate that is present in the papillary dermis and is connected to the epidermis at multiple points with attachment to the follicular outer root sheath. Peripheral palisading is characteristically present above an eosinophilic basement membrane (Figure, A). Rare reports have documented sebaceous and eccrine differentiation.5,6
Tumor of follicular infundibulum has been reported to be associated with other tumors. Organoid nevus (nevus sebaceous), trichilemmal tumor, and fibroma have been reported to occur as a collision tumor with tumor of follicular infundibulum. An association with Cowden disease also has been described.7 Biopsies that represent partial samples should be interpreted cautiously, as step sections can reveal basal cell carcinoma.
The term sclerosing epithelial neoplasm describes tumors that share a paisley tielike epithelial pattern and sclerotic stroma. Small specimens often require clinicopathologic correlation (Figure, C). The differential diagnosis includes morpheaform basal cell carcinoma, desmoplastic trichoepithelioma, and microcystic adnexal carcinoma. A panel of stains using Ber-EP4, PHLDA1, cytokeratin 15, and cytokeratin 19 has been proposed to help differentiate these entities.8 CD34 and cytokeratin 20 also have been used with varying success in small specimens.9,10
- Ferringer T, Peckham S, Ko CJ, et al. Melanocytic neoplasms. In: Elston DM, Ferringer T, eds. Dermatopathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2014:105-109.
- Headington JT. Tumors of the hair follicle. Am J Pathol. 1976;85:480-505.
- Davis DA, Cohen PR. Hair follicle nevus: case report and review of the literature. Pediatr Dermatol. 1996;13:135-138.
- Ikeda S, Kawada J, Yaguchi H, et al. A case of unilateral, systematized linear hair follicle nevi associated with epidermal nevus-like lesions. Dermatology. 2003;206:172-174.
- Mehregan AH. Hair follicle tumors of the skin. J Cutan Pathol. 1985;12:189-195.
- Mahalingam M, Bhawan J, Finn R, et al. Tumor of the follicular infundibulum with sebaceous differentiation. J Cutan Pathol. 2001;28:314-317.
- Cribier B, Grosshans E. Tumor of the follicular infundibulum: a clinicopathologic study. J Am Acad Dermatol. 1995;33:979-984.
- Sellheyer K, Nelson P, Kutzner H, et al. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40:363-370.
- Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311-315.
- Smith KJ, Williams J, Corbett D, et al. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25:464-471.
- Ferringer T, Peckham S, Ko CJ, et al. Melanocytic neoplasms. In: Elston DM, Ferringer T, eds. Dermatopathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2014:105-109.
- Headington JT. Tumors of the hair follicle. Am J Pathol. 1976;85:480-505.
- Davis DA, Cohen PR. Hair follicle nevus: case report and review of the literature. Pediatr Dermatol. 1996;13:135-138.
- Ikeda S, Kawada J, Yaguchi H, et al. A case of unilateral, systematized linear hair follicle nevi associated with epidermal nevus-like lesions. Dermatology. 2003;206:172-174.
- Mehregan AH. Hair follicle tumors of the skin. J Cutan Pathol. 1985;12:189-195.
- Mahalingam M, Bhawan J, Finn R, et al. Tumor of the follicular infundibulum with sebaceous differentiation. J Cutan Pathol. 2001;28:314-317.
- Cribier B, Grosshans E. Tumor of the follicular infundibulum: a clinicopathologic study. J Am Acad Dermatol. 1995;33:979-984.
- Sellheyer K, Nelson P, Kutzner H, et al. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40:363-370.
- Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311-315.
- Smith KJ, Williams J, Corbett D, et al. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25:464-471.
A 54-year-old man presented with a flesh-colored lesion on the chin. The nodule measured 0.6 cm in diameter. There was an underlying sclerotic plaque with indistinct borders.
Redness and Painful Ulcerations in the Perineal Area
The Diagnosis: PELVIS Syndrome
Infantile hemangiomas (IHs) are present in up to 10% of infants by 1 year of age and are most commonly located on the face and upper extremities. Less than 10% of IHs develop in the perineum.1 Perineal IHs are benign tumors of the vascular endothelium that present as plaques and commonly are accompanied by painful ulcerations. Ulceration is more common in the diaper area secondary to irritation from urine, stool, and friction.2 Although most IHs are benign isolated findings, facial IHs have been associated with several syndromes including Sturge-Weber and PHACE (posterior fossa brain malformations, hemangiomas, arterial anomalies, cardiac anomalies and coarctation of the aorta, and eye and endocrine abnormalities) syndromes.3 Researchers also have identified an association between lumbosacral IHs and spinal dysraphism (tethered spinal cord).4
A smaller number of studies have investigated congenital anomalies related to perineal IH,1,5 specifically PELVIS syndrome. The acronym PELVIS has been used to describe a syndrome of congenital malformations including perineal hemangioma, external genital malformations, lipomyelomeningocele, vesicorenal abnormalities, imperforate anus, and skin tag.1 An alternative description of similar findings is LUMBAR (lower body hemangioma and other cutaneous defects; urogenital anomalies, ulceration; myelopathy; bony deformities; anorectal malformations, arterial anomalies; and renal anomalies).5 Researchers have suggested that both of these acronyms describe the same syndrome, and it is common for the syndrome to be incomplete.6 One study (N=11) found that perineal hemangiomas are most commonly associated with anal malformations (8 patients), followed by urinary tract abnormalities (7 patients) and malformation of the external genitalia (7 patients). A skin tag was present in 5 patients.1 The pathogenesis of PELVIS syndrome is unknown.
When an infant presents with a perineal hemangioma and physical examination suggests PELVIS syndrome, imaging should be performed to evaluate for other anomalies. Before 4 months of age, ultrasound should be utilized to investigate the presence of reno-genitourinary or spinal malformations. Magnetic resonance imaging is the preferred imaging modality in children older than 4 months.7 Management of PELVIS syndrome requires a multidisciplinary approach and early recognition of the full extent of congenital malformations. Pediatric dermatologists, urologists, endocrinologists, and neonatologists have a role in its diagnosis and treatment.
- Girard C, Bigorre M, Guillot B, et al. PELVIS syndrome. Arch Dermatol. 2006;142:884-888.
- Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477-496.
- Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307-311.
- Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics. 1989;83:977-980.
- Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157:795-801.
- Frade FN, Kadlub V, Soupre S, et al. PELVIS or LUMBAR syndrome: the same entity. two case reports. Arch Pediatr. 2012;19:55-58.
- Berk DR, Bayliss SJ, Merritt DF. Management quandary: extensive perineal infantile hemangioma with associated congenital anomalies: an example of the PELVIS syndrome. J Pediatr Adolesc Gynecol. 2007;20:105-108.
The Diagnosis: PELVIS Syndrome
Infantile hemangiomas (IHs) are present in up to 10% of infants by 1 year of age and are most commonly located on the face and upper extremities. Less than 10% of IHs develop in the perineum.1 Perineal IHs are benign tumors of the vascular endothelium that present as plaques and commonly are accompanied by painful ulcerations. Ulceration is more common in the diaper area secondary to irritation from urine, stool, and friction.2 Although most IHs are benign isolated findings, facial IHs have been associated with several syndromes including Sturge-Weber and PHACE (posterior fossa brain malformations, hemangiomas, arterial anomalies, cardiac anomalies and coarctation of the aorta, and eye and endocrine abnormalities) syndromes.3 Researchers also have identified an association between lumbosacral IHs and spinal dysraphism (tethered spinal cord).4
A smaller number of studies have investigated congenital anomalies related to perineal IH,1,5 specifically PELVIS syndrome. The acronym PELVIS has been used to describe a syndrome of congenital malformations including perineal hemangioma, external genital malformations, lipomyelomeningocele, vesicorenal abnormalities, imperforate anus, and skin tag.1 An alternative description of similar findings is LUMBAR (lower body hemangioma and other cutaneous defects; urogenital anomalies, ulceration; myelopathy; bony deformities; anorectal malformations, arterial anomalies; and renal anomalies).5 Researchers have suggested that both of these acronyms describe the same syndrome, and it is common for the syndrome to be incomplete.6 One study (N=11) found that perineal hemangiomas are most commonly associated with anal malformations (8 patients), followed by urinary tract abnormalities (7 patients) and malformation of the external genitalia (7 patients). A skin tag was present in 5 patients.1 The pathogenesis of PELVIS syndrome is unknown.
When an infant presents with a perineal hemangioma and physical examination suggests PELVIS syndrome, imaging should be performed to evaluate for other anomalies. Before 4 months of age, ultrasound should be utilized to investigate the presence of reno-genitourinary or spinal malformations. Magnetic resonance imaging is the preferred imaging modality in children older than 4 months.7 Management of PELVIS syndrome requires a multidisciplinary approach and early recognition of the full extent of congenital malformations. Pediatric dermatologists, urologists, endocrinologists, and neonatologists have a role in its diagnosis and treatment.
The Diagnosis: PELVIS Syndrome
Infantile hemangiomas (IHs) are present in up to 10% of infants by 1 year of age and are most commonly located on the face and upper extremities. Less than 10% of IHs develop in the perineum.1 Perineal IHs are benign tumors of the vascular endothelium that present as plaques and commonly are accompanied by painful ulcerations. Ulceration is more common in the diaper area secondary to irritation from urine, stool, and friction.2 Although most IHs are benign isolated findings, facial IHs have been associated with several syndromes including Sturge-Weber and PHACE (posterior fossa brain malformations, hemangiomas, arterial anomalies, cardiac anomalies and coarctation of the aorta, and eye and endocrine abnormalities) syndromes.3 Researchers also have identified an association between lumbosacral IHs and spinal dysraphism (tethered spinal cord).4
A smaller number of studies have investigated congenital anomalies related to perineal IH,1,5 specifically PELVIS syndrome. The acronym PELVIS has been used to describe a syndrome of congenital malformations including perineal hemangioma, external genital malformations, lipomyelomeningocele, vesicorenal abnormalities, imperforate anus, and skin tag.1 An alternative description of similar findings is LUMBAR (lower body hemangioma and other cutaneous defects; urogenital anomalies, ulceration; myelopathy; bony deformities; anorectal malformations, arterial anomalies; and renal anomalies).5 Researchers have suggested that both of these acronyms describe the same syndrome, and it is common for the syndrome to be incomplete.6 One study (N=11) found that perineal hemangiomas are most commonly associated with anal malformations (8 patients), followed by urinary tract abnormalities (7 patients) and malformation of the external genitalia (7 patients). A skin tag was present in 5 patients.1 The pathogenesis of PELVIS syndrome is unknown.
When an infant presents with a perineal hemangioma and physical examination suggests PELVIS syndrome, imaging should be performed to evaluate for other anomalies. Before 4 months of age, ultrasound should be utilized to investigate the presence of reno-genitourinary or spinal malformations. Magnetic resonance imaging is the preferred imaging modality in children older than 4 months.7 Management of PELVIS syndrome requires a multidisciplinary approach and early recognition of the full extent of congenital malformations. Pediatric dermatologists, urologists, endocrinologists, and neonatologists have a role in its diagnosis and treatment.
- Girard C, Bigorre M, Guillot B, et al. PELVIS syndrome. Arch Dermatol. 2006;142:884-888.
- Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477-496.
- Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307-311.
- Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics. 1989;83:977-980.
- Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157:795-801.
- Frade FN, Kadlub V, Soupre S, et al. PELVIS or LUMBAR syndrome: the same entity. two case reports. Arch Pediatr. 2012;19:55-58.
- Berk DR, Bayliss SJ, Merritt DF. Management quandary: extensive perineal infantile hemangioma with associated congenital anomalies: an example of the PELVIS syndrome. J Pediatr Adolesc Gynecol. 2007;20:105-108.
- Girard C, Bigorre M, Guillot B, et al. PELVIS syndrome. Arch Dermatol. 2006;142:884-888.
- Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477-496.
- Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307-311.
- Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics. 1989;83:977-980.
- Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157:795-801.
- Frade FN, Kadlub V, Soupre S, et al. PELVIS or LUMBAR syndrome: the same entity. two case reports. Arch Pediatr. 2012;19:55-58.
- Berk DR, Bayliss SJ, Merritt DF. Management quandary: extensive perineal infantile hemangioma with associated congenital anomalies: an example of the PELVIS syndrome. J Pediatr Adolesc Gynecol. 2007;20:105-108.
A 7-week-old boy with ambiguous genitalia presented for evaluation of what the parents described as progressively worsening diaper rash. The patient was born at full-term after an uncomplicated gestation via normal spontaneous vaginal delivery. Examination of the external genitalia revealed microphallus with phimosis and a bifid scrotum. Two weeks after birth, the patient developed redness and painful ulcerations in the diaper area. At the time of presentation, the patient had bright red plaques along the suprapubic lines, inguinal creases, and in the perineal region. Physical examination also was notable for tender ulcerations of the inguinal creases and perineum and a perineal skin tag.